文献速递脑血管病神经重症与神经感染

max-ICH评分在脑出血中的多中心验证

Multicenter Validation of the max-ICH Score in Intracerebral Hemorrhage.
PubMed 文献 · Ann Neurol · 2020-12-21

这项多中心验证研究纳入4677例自发性脑出血患者,比较max-ICH评分与ICH评分对长期功能结局的预测效能。max-ICH评分在不限早期治疗限制的患者中区分度优于ICH评分,且在高阈值概率下临床净获益更高。

要点

  • max-ICH评分对脑出血长期功能结局的预测区分度优于ICH评分。
  • 两种评分均未显示校准不良的证据。
  • 在高阈值概率下,max-ICH评分较ICH评分提供临床净获益。

核心结论

  • max-ICH评分对脑出血后功能结局提供有效且更优的预测。
  • 其减少错误预测不良结局的临床净获益可能避免不必要的治疗限制。

研究设计与样本

  • 多中心验证研究,比较max-ICH评分与ICH评分的诊断准确性和临床效用。
  • 纳入4677例连续自发性脑出血患者,来自2项德国回顾性研究、1项德国前瞻性单中心研究和1项美国前瞻性纵向单中心研究。
  • 患者治疗时间范围为2006年1月至2015年12月。

主要发现

  • 4677例患者中1017例(21.7%)存在早期治疗限制;德国队列为15.6%(440/2377),MGH为31.0%(577/1283)。
  • 无早期治疗限制患者中,max-ICH评分与ICH评分的AUROC:德国队列0.81(0.78-0.83) vs 0.74(0.72-0.77),p<0.01;MGH 0.85(0.81-0.89) vs 0.78(0.74-0.82),p<0.01。
  • 全队列中,max-ICH评分与ICH评分的AUROC:德国队列0.84(0.82-0.86) vs 0.80(0.77-0.82),p<0.01;MGH 0.83(0.81-0.85) vs 0.77(0.75-0.79),p<0.01。
  • 两种评分均未显示校准不良的证据。
  • 在高阈值概率(0.8,旨在避免假阳性不良结局归因)下,max-ICH评分较ICH评分提供临床净获益(每100例患者净预测不良结局14.1 vs 2.1)。

临床怎么用

  • max-ICH评分可用于脑出血患者长期功能结局的预测,尤其适用于避免早期治疗限制偏倚的场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Outcome prognostication unbiased by early care limitations (ECL) is essential for guiding treatment in patients presenting with intracerebral hemorrhage (ICH). The aim of this study was to determine whether the max-ICH (maximally treated ICH) Score provides improved and clinically useful prognostic estimation of functional long-term outcomes after ICH. METHODS: This multicenter validation study compared the prognostication of the max-ICH Score versus the ICH Score regarding diagnostic accuracy (discrimination and calibration) and clinical utility using decision curve analysis. We performed a joint investigation of individual participant data of consecutive spontaneous ICH patients (n = 4,677) from 2 retrospective German-wide studies (RETRACE I + II; anticoagulation-associated ICH only) conducted at 22 participating centers, one German prospective single-center study (UKER-ICH; nonanticoagulation-associated ICH only), and 1 US-based prospective longitudinal single-center study (MGH; both anticoagulation- and nonanticoagulation-associated ICH), treated between January 2006 and December 2015. RESULTS: Of 4,677 included ICH patients, 1,017 (21.7%) were affected by ECL (German cohort: 15.6% [440 of 2,377]; MGH: 31.0% [577 of 1,283]). Validation of long-term functional outcome prognostication by the max-ICH Score provided good and superior discrimination in patients without ECL compared with the ICH Score (area under the receiver operating curve [AUROC], German cohort: 0.81 [0.78-0.83] vs 0.74 [0.72-0.77], p < 0.01; MGH: 0.85 [0.81-0.89] vs 0.78 [0.74-0.82], p < 0.01), and for the entire cohort (AUROC, German cohort: 0.84 [0.82-0.86] vs 0.80 [0.77-0.82], p < 0.01; MGH: 0.83 [0.81-0.85] vs 0.77 [0.75-0.79], p < 0.01). Both scores showed no evidence of poor calibration. The clinical utility investigated by decision curve analysis showed, at high threshold probabilities (0.8, aiming to avoid false-positive poor outcome attribution), that the max-ICH Score provided a clinical net benefit compared with the ICH Score (14.1 vs 2.1 net predicted poor outcomes per 100 patients). INTERPRETATION: The max-ICH Score provides valid and improved prognostication of functional outcome after ICH. The associated clinical net benefit in minimizing false poor outcome attribution might potentially prevent unwarranted care limitations in patients with ICH. ANN NEUROL 2021;89:474-484.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Sembill JA, Castello JP, Sprügel MI, et al. Multicenter Validation of the max-ICH Score in Intracerebral Hemorrhage. Ann Neurol. 2020. PMID: 33222266. doi:10.1002/ana.25969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。